NYSE:NNVC
Nanoviricides, Inc.
Nanoviricides, Inc.'s revenue was $0 in fiscal 2026. Free cash flow was −$7.8M, and the diluted share count rose 33.5%.Summary generated from Nanoviricides, Inc.'s SEC filings. Latest annual report filed Sep 28, 2026.
Key statistics
Fiscal 2026 from SEC filings. MethodologyRevenue (FY26)$0
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−101.5%
Debt / equityn/a
Free cash flow−$7.8M
FCF marginn/a
Share count change+33.5%
Financials
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | n/a | 0 | 0 | 0 | 0 |
| Operating income | −8 | −9 | −9 | −10 | −8 |
| Net income | −8 | −9 | −8 | −9 | −8 |
| Free cash flow | −6 | −6 | −6 | −9 | −8 |
Recent filings
- DEF 14AProxy statement
Oct 8, 2026 - 8-KDirector or officer change
Sep 29, 2026 - 10-KAnnual report for the fiscal year ended Jun 30, 2026
Sep 28, 2026 - 8-KEntry into a material agreement
Jul 30, 2026 - 8-KEntry into a material agreement
Jul 17, 2026 - 8-KRegulation FD disclosure
May 21, 2026 - 8-KEntry into a material agreement
May 20, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 15, 2026